Abstracts tagged "Rheumatic disease"

Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Edward Lee¹, Robert Suruki², Brian Carpenter³, Ty Harkness³, Daniel Luk⁴ and Mohamed Yassine¹, ¹UCB Pharma, Smyrna, GA, ²UCB Pharma, Raleigh, NC, ³Charles River Associates, New York, NY, ⁴Charles River Associates, Boston, MA
Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…
Abstract Number: 81 • 2017 ACR/ARHP Annual Meeting
Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis
Eric Lowe¹, Janet Anderl¹, R Andrea Fan¹, Henry W. B. Johnson², Christopher J Kirk³ and Tony Muchamuel⁴, ¹Biology, Kezar Life Sciences, South San Francisco, CA, ²Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor (PI) PR-957/ONX 0914 blocks cytokine production in vitro and attenuates disease progression in experimental models of rheumatoid arthritis (RA) (Nature Medicine…
Abstract Number: 509 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Mark C. Genovese¹, Joel Kremer², Sheng Zhong³ and Alan Friedman³, ¹Stanford University Medical Center, Palo Alto, CA, ²Albany Medical College, Albany, NY, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis…
Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
Ruediger Mueller¹, Frederik Mattow², Florian Popp³ and Johannes von Kempis⁴, ¹Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Rorschacherstrasse 95, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…
Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nathaniel Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
Abstract Number: 118 • 2017 Pediatric Rheumatology Symposium
Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease
Rebecca Trachtman¹, Alexa Adams², Nancy Pan², Sarah Taber² and Karen Onel², ¹Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, ²Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: Pediatric rheumatology patients are at high risk for the development of pulmonary disease. Lung disease in these patients can go unnoticed for long periods…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 932 • 2016 ACR/ARHP Annual Meeting
High Symptom Prevalence and Under-Utilisation of Palliative Care at End-of-Life of Patients with Systemic Rheumatic Diseases
Jiacai Cho¹, Dominic Lo², Anselm Mak^1,2, Jamie Zhou³ and Sen Hee Tay^1,2, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, ³Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, National University Health System, Singapore, Singapore, Singapore
Background/Purpose: Patients with rheumatic diseases may have systemic complications from disease as well as therapy and often suffer symptoms towards the end-of-life comparable to patients…
Abstract Number: 1352 • 2016 ACR/ARHP Annual Meeting
Predictors of Mortality in Rheumatic Disease Patients with CMV Infection
Kyoung Yong Lee¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Immunosuppressive therapy, which is frequently used to treat various rheumatic diseases, increases risk of opportunistic infection. However, few reports were available on the prognosis…
Abstract Number: 2458 • 2016 ACR/ARHP Annual Meeting
Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
Omid Zahedi Niaki¹, Christian A. Pineau², Sasha Bernatsky^3,4 and Evelyne Vinet³, ¹Université de Montréal, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given the obvious female predominance of rheumatic diseases, significant attention has already been drawn to the impact of these conditions on female sexual function.…
Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Iain B. McInnes¹, Joel Kremer², Paul Emery³, Steven H. Zuckerman⁴, Giacomo Ruotolo⁴, Chadi Saifan⁴, Lei Chen⁴, Shayami Thanabalasundrum⁴, Sarah Witt⁴ and William Macias⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³University of Leeds, Midlothian, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
Abstract Number: 1215 • 2015 ACR/ARHP Annual Meeting
Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis
Gavin Sun¹, Glen Hazlewood², Sasha Bernatsky³, Gilaad Kaplan⁴, Bertus Eksteen⁵ and Cheryl Barnabe², ¹Department of Internal Medicine, University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Division of Hepatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases, including rheumatoid arthritis (RA),…
Abstract Number: 1352 • 2015 ACR/ARHP Annual Meeting
How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors
Jorge Gaspar Ramos¹, Dafhne Miranda², Pilar Cruz-Dominguez³, Luis Javier Jara⁴ and Miguel A. Saavedra⁵, ¹Rheumatology, Hospital de Especialidades, Dr. Antonio Fraga Mouret, Centro Medico Nacional La Raza, IMSS, Mexico City, Mexico, ²Rheumatology, Rheumatology Unit, Hospital de Especialidades. Centro Médico La Raza, IMSS, Distrito federal, Mexico, ³Centro Médico Nacional La Raza IMSS, México, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁵Reumatología, Centro Médico Nacional La Raza IMSS, México DF., México D.F., Mexico
Background/Purpose: Anti-tumor necrosis factor-α (TNF-α) therapy is associated with an increased risk of mycobacterium tuberculosis infection. Tuberculosis (TB) reactivation can lead to severe complications in…
Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting
There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach
Sindhu Johnson¹, Medha Soowamber², Jaap Fransen³, Dinesh Khanna⁴, Frank H.J. van den Hoogen⁵, Murray Baron⁶, Marco Matucci Cerinic⁷, Christopher P. Denton⁸, Thomas A. Medsger Jr.⁹, Patricia E. Carreira¹⁰, Gabriela Riemekasten¹¹, Jorg HW. Distler¹², Armando Gabrielli¹³, Virginia D. Steen¹⁴, Lorinda Chung¹⁵, Richard Silver¹⁶, John Varga¹⁷, Ulf Müller-Ladner¹⁸, Madelon C. Vonk¹⁹, Ulrich A. Walker²⁰, Frank Wollheim²¹, Ariane L. Herrick²², Daniel E. Furst²³, Lazlo Czirjak²⁴, Otylia Kowal-Bielecka²⁵, Francesco Del Galdo²⁶, Maurizio Cutolo²⁷, Nicolas Hunzelmann²⁸, Charles Murray²⁹, Ivan Foeldvari³⁰, Luc Mouthon³¹, Nemanja Damjanov³², Bashar Kahaleh³³, Tracy M. Frech³⁴, Shervin Assassi³⁵, Lesley Ann Saketkoo³⁶ and Janet E. Pope³⁷, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁷Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ⁸Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, ⁹Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, ¹⁰Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Human medicine, BERLIN, Germany, ¹²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹³Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ¹⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹⁶Div Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁷Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Rheumatology, Internal Medicine, Bad Nauheim, Germany, ¹⁹Rheumatology, Rheumatology, Nijmegen, Netherlands, ²⁰Rheumatology, Systemic Sclerosis, Basel, Switzerland, ²¹Rheumatology, Lund University Hospital, Lund, Sweden, ²²Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²⁴University of Pécs Medical Center, Pécs, Hungary, ²⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²⁸Department of Dermatology, University of Cologne, Cologne, Germany, ²⁹Department of Gastroenterology, Royal Free Hospital, London, United Kingdom, ³⁰Rheumatology, Hamburg, Germany, ³¹Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ³²Resavska 69, Institute of Rheumatology, Belgrade, Serbia, ³³Medicine/Rheumatology, The University of Toledo, Toledo, OH, ³⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ³⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³⁶Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³⁷University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…
Abstract Number: 2525 • 2015 ACR/ARHP Annual Meeting
Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions
Rishi J. Desai¹, Krista Huybrechts², Brian Bateman², Sonia Hernandez-diaz³, Helen Mogun², Chandrasekar Gopalakrishnan⁴, Elisabetta Patorno⁴ and Seoyoung C. Kim⁵, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic inflammatory conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) affect many women during their…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].